Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tanabe Pharma America, Inc.
Age
18–49
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Provide written informed consent to participate in this study
Agree to approximately 30-90 day washout interval of hormonal therapies, if applicable
Have a history of regular menstrual cycles
Have a body mass index \< 45 kg/m\^2 (inclusive)
Have documented surgical/laparoscopy diagnosis of endometriosis with 10 years
Agree to use 2 forms of nonhormonal contraception throughout the study
In the Investigator's opinion, subject is able to understand the nature of the study and any risk involved in participation, and is willing to cooperate and comply with the protocol restrictions and requirements including transvaginal ultrasound.
Have moderate to severe endometrial related pain
You may not be if
Subject is pregnant, breast feeding, or planning a pregnancy.
Subject is \< 6 months postpartum, postabortion, or post-pregnancy.
Willing to remove a hormonal intrauterine device (IUD) at least 30 days prior to screening. (Non hormonal IUDs do not have to be removed)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) , or total bilirubin ≥ 2.0 × upper limit of normal (ULN) above the reference range
Have immunosuppression due to underlying medical condition
Corrected QT interval using Fridericia's formula (QTcF) or Corrected QT interval using Bazett's formula (QTcB) ≥ 450 msec or clinically important abnormal findings on the ECG
Subject is not up-to-date on breast screening according to current guidelines.
Has a surgical history of hysterectomy, bilateral oophorectomy and any other recent major surgery
Subject is required more than 2 weeks of continuous use of prohibited long-acting narcotic or immediate release narcotic for treatment of endometriosis-associated pain.
Have chronic pelvic pain for nonendometriosis related causes, which require systemic pharmaceutical chronic therapy for pain
Have other chronic pain syndrome which require chronic analgesic or other chronic therapy
Have a clinically significant gynecologic condition identified on the transvaginal ultrasound (TVU) (e.g., complex ovarian cyst \> 3 cm or simple ovarian cyst \> 5 cm, clinically significant endometrial pathology, single fibroid ≥ 4 cm or multiple (\> 4) fibroids that measure ≥ 2 cm or symptomatic submucosal fibroid of any size
Have a current history of undiagnosed abnormal genital bleeding
Clareo Health | Safety and Efficacy Study of MT-2990 in Women With Endometriosis
